98%
921
2 minutes
20
Introduction: Neck of femur (NOF) fractures constitute a significant proportion of the workload of orthopaedic departments, with approximately 65 000 admissions across the UK annually. There are various surgical procedures available to repair NOF fractures and each is associated with numerous intraoperative and perioperative risks. Informed consent is an essential part of the workup when planning to undertake any surgical procedure, whereby the risks and benefits of surgery are discussed with the patient, so they are able to make decisions about their care. It is therefore important that consent forms are sufficiently detailed and accurate to ensure consent is fully informed.
Method: We performed a multi-loop audit of consent forms for patients admitted to the Royal Oldham Hospital (United Kingdom) with NOF fracture. The frequency that different risks were included on consent forms was compared to the British Orthopaedic Association (BOA)-produced standardised list of risks for NOF fracture procedures.
Results: We found that on each consent form an average of only 56.6 % of risks were included before intervention. Some significant risks such as mortality were frequently missed. Following this, we implemented changes to the consent process including the use of stickers to use on consent forms and team education sessions. We subsequently performed a second audit cycle and found that compliance had increased to 87.9 %.
Conclusion: Overall, there was poor documentation of surgical risks on consent forms, however this was improved with basic interventions. A further audit cycle should be recommended to investigate if this improvement is sustained.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697277 | PMC |
http://dx.doi.org/10.1016/j.jcot.2024.102867 | DOI Listing |
BMC Infect Dis
September 2025
Department Health and Prevention, Institute of Psychology, University of Greifswald, Robert-Blum-Str. 13, Greifswald, 17489, Germany.
Background: Healthcare workers (HCWs) played a crucial role in dealing with the COVID-19 pandemic. In addition to increased workloads, they were confronted with stigmatization due to their work in the health sector.
Methods: Guided by the Health Stigma and Discrimination Framework (HSDF), this study aimed to explore the experiences of stigmatization of HCWs in Germany using semi-structured interviews (N = 34) and investigate effective coping strategies and existing needs in this context.
Eye (Lond)
September 2025
Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Delhi, India.
Eur Arch Psychiatry Clin Neurosci
September 2025
Tianjin Anding Hospital, Institute of Mental Health, Psychiatric Medical Center of Tianjin University, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China.
Background: Elevated homocysteine levels, known as hyperhomocysteinemia (HHcy), have been implicated in the pathophysiology of schizophrenia. Most prior studies focused on first-episode or acute-phase schizophrenia patients, leaving the prevalence, determinants, and clinical correlates of HHcy in chronic schizophrenia understudied. This study aims to investigate the prevalence and determinants of HHcy in patients with chronic schizophrenia, as well as its clinical correlates.
View Article and Find Full Text PDFCureus
August 2025
Haematology, Bon Secours Hospital, Cork, IRL.
Introduction: Venous thromboembolism (VTE), mainly deep vein thrombosis (DVT) and pulmonary embolism (PE), persists as a critical contributor to hospital-acquired mortality. Despite its largely preventable nature, early 2024 data from Bon Secours Hospital in Cork revealed alarmingly low compliance with VTE prophylaxis protocol.
Aim: This study evaluated the implementation efficacy of VTE risk assessment and prophylaxis in adult hospitalised patients at Bon Secours Hospital, Cork, according to National Institute for Health and Care Excellence (NICE) guidelines.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDF